Important pharmacy news and late-breaking industry information updated daily.
The pharmacy community suffered another disappointment at the hands of the Trump administration when a planned end to “safe harbor” protections under the federal anti-kickback statute for the rebates prescription drug manufacturers pay to PBMs was scuttled. The ambitious proposal reportedly could not withstand fears it would increase premiums for Medicare Part D beneficiaries—a frequent PBM talking point. Advocates for direct and indirect remuneration (DIR) reform were still reeling from May’s abandonment of a CMS Medicare requiring all price concessions to be assessed at point of sale.
Novartis on July 9 that it will make its generic prefilled epinephrine shots (Symjepi) immediately available in all U.S. pharmacies.
With measles cases climbing to nearly 2,000 this summer, awareness about the MMR vaccine is more significant than it has been in decades—the same goes for access.
The Third Circuit Court of Appeals unanimously upheld a lower court decision blocking a revised set of Trump administration rules allowing employers with religious or moral objections to opt out of providing their workers with birth-control coverage.
President Trump signed on Wednesday an executive order aimed at improving medical care for people with kidney disease.
With the "season" for acute flaccid myelitis (AFM) approaching, CDC is urging health care professionals to rapidly recognize the symptoms of the disease and report all suspected to cases to their local health department.
A new published in Arthritis Care & Research found that it’s common for patients with gout to be discharged from the emergency department (ED) with a prescription for opioids.
U.S. District Court Judge Amit Mehta on Monday ruled the Trump administration overstepped its authority with a rule to force drug companies to include the price of their medicine in television advertisements.
Several states, including Virginia and Vermont, have laws mandating that clinicians coprescribe naloxone with opioids to high-risk patients. A new published in JAMA Network Open suggests that these legal mandates are associated with substantial increases in naloxone dispensing.
President Trump on Friday said his administration is writing an executive order to require drug manufacturers to offer the United States government among the lowest prices in the world, in comments that were not immediately clear to many experts on the nation's health care system.